With Corlanor Approval, Amgen Kicks Its CV Push Into High Gear
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will launch the heart failure drug within one week, creating a chance to build rapport with cardiologists ahead of potential launch of the PCSK9 blocker evolocumab later this year.